The Board's Verdict: A Turnaround That Ran Out of Time
Sanofi's board didn't wait for a graceful exit. On February 11, it declined to renew Paul Hudson's director mandate — effective February 17 — ending a six-year tenure that began with a sweeping mandate to rebuild one of Europe's largest pharmaceutical companies. The decision was not a firing in name, but in substance it was precisely that. Olivier Charmeil, EVP of General Medicines and a Sanofi executive committee member since 2011, steps in as Interim CEO until the Annual General Meeting on April 29, when Belén Garijo officially assumes command, pending shareholder votes on both her directorship and a bylaw amendment to raise the CEO age limit.
That bylaw change — required because Garijo is 65 — is itself a signal: the board wanted her specifically, and moved bureaucratic obstacles to get her.
Why Hudson Lost the Board's Confidence
Hudson was hired in 2019 to solve a single existential problem: Dupixent, Sanofi's blockbuster immunology drug co-developed with Regeneron, generates over €15 billion in annual sales but faces patent expiration in the early 2030s. His mandate was to build what comes next. He didn't deliver it fast enough.
The evidence is damning in aggregate. Key late-stage trials produced mixed or negative results through 2025, including regulatory hurdles for tolebrutinib in neurology. Sanofi's vaccine division, meant to be a growth pillar, posted a 2.5% year-on-year sales decline in 2025 despite a 31.5% rise in its COVID-19 portfolio — a net result well below expectations. The stock lost approximately 25% of its value over the past year. On a January 2026 earnings call, Hudson himself acknowledged that plans "had not moved as quickly as anticipated."
The board's language in the announcement is precise and deliberately chosen: Garijo's priority will be "increased rigor" in the "productivity, governance, and innovation capacity of Research & Development." Translated from boardroom into plain English — the strategy was defensible; the execution was not.
Who Is Belén Garijo, and What Is Sanofi Buying?
Garijo is not an outsider gamble. She is a medical doctor with six years of clinical practice, followed by stints at Abbott and then 15 years at Sanofi itself — where she rose to VP of Pharmaceutical Operations for Europe and Canada and led the complex integration of Genzyme during its acquisition. She then joined Merck KGaA in 2011 and became its CEO in 2021, making history as the first woman to lead a DAX40 company in Germany. She also serves on the board of BBVA and served on L'Oréal's board for a decade.
At Merck KGaA, she pursued meaningful portfolio actions, including the $3.9 billion acquisition of Springworks, closed in July 2025. She has been ranked among Forbes' and Fortune's Most Powerful Women consistently.
This is an execution hire, not a vision hire. The board is not asking Garijo to reimagine Sanofi's scientific direction — it's asking her to convert spend into approvals, labels, and commercial launches on schedule. Her prior 15 years inside Sanofi means she can diagnose cultural and process failures faster than any external candidate. The risk is the inverse: she may instinctively "fix from within" rather than make the disruptive portfolio cuts the pipeline may require.
The Investor's Cold Calculation: Bull Case, Bear Case, Base Case
Sanofi's ADR trades at $49.25, down roughly 5–6% on announcement day. BofA downgraded to "neutral" with a revised €92 target (from €102), citing limited 2026 catalysts and a "period of rebuild." The market's verdict is clear: this is a show-me story now.
The bull case rests on portfolio concentration — Garijo enforcing tighter go/no-go decisions in immunology and specialty, pairing operational discipline with smart bolt-on M&A, and shifting the narrative from "we are investing" to "we are delivering." If late-stage conversion rates improve, the market can begin re-underwriting the post-Dupixent era.
The bear case is that "rigor" curdles into risk aversion — an incrementalist pipeline that cannot compete against best-in-class biologics, compounded by talent churn and program delays during transition. If 2026 readouts disappoint before Garijo has even set foot in the role, Sanofi risks being re-rated as a structural value trap.
The base case is mildly constructive: this change raises the probability that Sanofi stops losing credibility in R&D execution. But it is not an automatic re-rating event. Investors should track three things with discipline — the kill rate on marginal programs, the clarity of phase 2-to-phase 3 conversion criteria, and whether capital allocation tilts toward targeted bolt-ons or a high-risk transformative deal. Early decisiveness from Garijo, before the AGM, would be the single most bullish signal available between now and April 29.
The Dupixent cliff remains the clock on the wall. It will not stop ticking for anyone.
not investment advice